Approval · Notice of Compliance 11540 · 2010
UROMAX: Notice of Compliance 11540
Issued June 18, 2010
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 11540
- Date
- June 18, 2010
- Company
- Purdue PharmaToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Revisions to Action and Clinical Pharmacology section of the Product Monograph
- Therapeutic class
- Anticholinergic / Antispasmodic
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| UROMAX | Not yet assigned | — |
Medicinal ingredients
- OXYBUTYNIN CHLORIDE 5 MG per TAB
- OXYBUTYNIN CHLORIDE 10 MG per TAB
- OXYBUTYNIN CHLORIDE 15 MG per TAB